BioCryst Pharmaceuticals press release ( BCRX ): Q1 GAAP EPS of -$2.98 misses by $3.03 . Revenue of $156.4M (+7.5% Y/Y) beats by $5.28M . Financial Outlook for 2026 The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB® (peramivir injection), to be between $635 millio...
BioCryst Pharmaceuticals press release ( BCRX ): Q1 GAAP EPS of -$2.98 misses by $3.03 . Revenue of $156.4M (+7.5% Y/Y) beats by $5.28M . Financial Outlook for 2026 The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB® (peramivir injection), to be between $635 million and $660 million. The company also maintained its expectation for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to be between $450 million and $470 million. Item As of May 6, 2026 As of February 26, 2026 ORLADEYO revenue Unchanged $625 million to $645 million Total revenue Unchanged $635 million to $660 million Non-GAAP operating expense Unchanged $450 million to $470 million Click to enlarge More on BioCryst Pharmaceuticals BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation BioCryst Pharmaceuticals Q1 2026 Earnings Preview BioCryst gains amid takeover speculation
(RTTNews) - Major stock markets in Asia surged on Wednesday tracking the strong gains in Wall Street, attributed to AI-momentum and U.S.-Iran peace deal hopes. Equity markets in Japan were closed for a holiday.
(RTTNews) - Major stock markets in Asia surged on Wednesday tracking the strong gains in Wall Street, attributed to AI-momentum and U.S.-Iran peace deal hopes. Equity markets in Japan were closed for a holiday.
Dragon Claws/iStock via Getty Images When I last covered Enterprise Products Partners ( EPD ), a big part of the thesis was that it was rapidly approaching a cash flow inflection point where it would be pivoting from investing aggressively in growth projects to seeing its free cash flow soar, its leverage plummet, and its ability to return capital to unit holders increase substantially. Since then...
Dragon Claws/iStock via Getty Images When I last covered Enterprise Products Partners ( EPD ), a big part of the thesis was that it was rapidly approaching a cash flow inflection point where it would be pivoting from investing aggressively in growth projects to seeing its free cash flow soar, its leverage plummet, and its ability to return capital to unit holders increase substantially. Since then, EPD has reported very strong first-quarter results, with first-quarter EBITDA up by 10% year-over-year , and management indicating that the coming quarters may end up being even better. This article will take a fresh look at EPD's business model as well as valuation to share my updated thoughts on it and on whether or not I think it's a buy right now. EPD's Formidable Positioning EPD has a lot going for it even before the recent macro developments pertaining to the Strait of Hormuz. For example, it has one of the largest and most integrated midstream networks in North America, including NGL pipelines, fractionation, natural gas gathering and processing infrastructure, crude oil pipelines, and marine export terminals. Additionally, it controls the whole value chain from wellhead to water as it takes in gas and liquids from producers and then outputs finished products for export. Moreover, it generates largely fee-based earnings as its gross operating margin runs around 74–82% for fee-based earnings, which means that its cash flows are not significantly swung one way or another during periods of commodity price volatility. Finally, about 90% of its long-term contracts have inflation escalators on them, which also makes it a solid inflation-resistant investment. EPD also has a phenomenal balance sheet, as it has the only A-minus credit rating in the entire midstream sector. On top of that, it delivered record operational performance in Q1, with: Natural gas processing volumes are up 7% year over year NGL fractionation volumes up 16% year over year Marine terminal loading vol...
Cyngn (NASDAQ: CYN) will announce its first quarter 2026 financial results for the period ended March 31, 2026, on Wednesday, May 13, 2026, after the close of market.
Cyngn (NASDAQ: CYN) will announce its first quarter 2026 financial results for the period ended March 31, 2026, on Wednesday, May 13, 2026, after the close of market.
InMode press release ( INMD ): Non-GAAP EPS of $0.25 misses by $0.05 . Revenue of $82M (+5.3% Y/Y) beats by $2.14M . Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025. ● GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million. ● Total cash position of $537.2 million as of March 31, 2026, including c...
InMode press release ( INMD ): Non-GAAP EPS of $0.25 misses by $0.05 . Revenue of $82M (+5.3% Y/Y) beats by $2.14M . Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025. ● GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million. ● Total cash position of $537.2 million as of March 31, 2026, including cash and cash equivalents, marketable securities and short-term bank deposits. ● As of March 31, 2026, we completed the repurchase of 2.55 million ordinary shares pursuant to our share repurchase program, returning $34.8 million of capital to shareholders ($3.6 million of which was paid during the second quarter of 2026). ● Announced CFO transition; Yair Malca steps down and will support an orderly transition as a consultant. More on InMode InMode: The Beauty Of A Value Trap InMode Ltd. (INMD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript InMode: Some Green Shoots Appearing, But The Market Hasn't Noticed InMode Q1 2026 Earnings Preview InMode sets new share repurchase program
Kyndryl Holdings press release ( KD ): Q4 Non-GAAP EPS of $0.18 misses by $0.29 . Revenue of $3.78B (-0.5% Y/Y) beats by $20M . Adjusted EBITDA was $688 million, compared to adjusted EBITDA of $698 million in the prior-year period. Free cash flow was $388 million in the quarter, compared to $353 million in the fourth quarter of fiscal 2025. Fiscal Year 2027 Outlook Kyndryl is providing the followi...
Kyndryl Holdings press release ( KD ): Q4 Non-GAAP EPS of $0.18 misses by $0.29 . Revenue of $3.78B (-0.5% Y/Y) beats by $20M . Adjusted EBITDA was $688 million, compared to adjusted EBITDA of $698 million in the prior-year period. Free cash flow was $388 million in the quarter, compared to $353 million in the fourth quarter of fiscal 2025. Fiscal Year 2027 Outlook Kyndryl is providing the following outlook for its fiscal year 2027: Adjusted pretax income of $600 to $700 million Consistent with our definition of adjusted pretax income since fiscal 2025, this includes workforce rebalancing charges Free cash flow of $400 to $500 million Constant-currency revenue flat to down 2% More on Kyndryl Holdings Kyndryl Holdings Q4 Preview: A Lot Of Work To Restore Investor Confidence Kyndryl Holdings, Inc. (KD) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Looking At Kyndryl After A 50%+ Drop Kyndryl Holdings Q4 2026 Earnings Preview Largest YTD losses among mid-cap stocks with A profitability grades
Geron press release ( GERN ): Q1 GAAP EPS of -$0.01 beats by $0.01 . Revenue of $51.84M (+30.9% Y/Y) beats by $1.25M . Grew RYTELO demand by 6% in the first quarter 2026, compared to the fourth quarter 2025. Increased ordering accounts by roughly 12% in the first quarter 2026 to approximately 1,450. For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 mil...
Geron press release ( GERN ): Q1 GAAP EPS of -$0.01 beats by $0.01 . Revenue of $51.84M (+30.9% Y/Y) beats by $1.25M . Grew RYTELO demand by 6% in the first quarter 2026, compared to the fourth quarter 2025. Increased ordering accounts by roughly 12% in the first quarter 2026 to approximately 1,450. For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million. Geron also expects total operating expenses to be between $230 million and $240 million. Shares -2.4% PM. More on Geron Geron: Minimal Sales Growth But A Potential Run-Up Ahead Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Geron: Why I'm Doubling Down On My 'Sell' Rating After Q4 Earnings Geron Q1 2026 Earnings Preview Geron falls as Q4 results miss expectations
vittaya pinpan MBA Mortgage Applications Composite Index: -4.4% to 285.3, compared to -1.6% to 298.5 in the prior week. Purchase Index: -3.7% to 171.1, vs. +1.2% to 177.7 a week ago. Refinance Index: -5.0% to 928.6, vs. -4.4% to 977.9 in the prior week. 30-year fixed-rate mortgages came in at 6.45%, compared to 6.37% last week. "The ongoing conflict in the Middle East continues to push rates highe...
vittaya pinpan MBA Mortgage Applications Composite Index: -4.4% to 285.3, compared to -1.6% to 298.5 in the prior week. Purchase Index: -3.7% to 171.1, vs. +1.2% to 177.7 a week ago. Refinance Index: -5.0% to 928.6, vs. -4.4% to 977.9 in the prior week. 30-year fixed-rate mortgages came in at 6.45%, compared to 6.37% last week. "The ongoing conflict in the Middle East continues to push rates higher. Mortgage rates last week increased to their highest level in a month," said Joel Kan, vice president and deputy chief economist at the Mortgage Bankers Association. "The average loan size on a purchase application increased to $467,300, the highest in the survey's history dating back to 1990. This increase could indicate that potential first-time buyers, and buyers looking for homes at lower price points, might be the most hesitant to move forward given the economic uncertainty and higher rates," said Kan. More related to Mortgages Mortgage rates rise after three weeks of decline Ten-year inflation expectations at highest point since '23 Housing starts rise in March; building permits fall
filo Shares of CVS Health ( CVS ) traded higher in the premarket on Wednesday after the managed care firm raised its full-year outlook following better-than-expected Q1 2026 earnings, largely driven by its Health Care Benefits segment, which houses its health insurer Aetna. The Woonsocket, Rhode Island-based healthcare giant increased its outlook for adjusted earnings per share to $7.30-$7.50 from...
filo Shares of CVS Health ( CVS ) traded higher in the premarket on Wednesday after the managed care firm raised its full-year outlook following better-than-expected Q1 2026 earnings, largely driven by its Health Care Benefits segment, which houses its health insurer Aetna. The Woonsocket, Rhode Island-based healthcare giant increased its outlook for adjusted earnings per share to $7.30-$7.50 from $7.00-$7.20, exceeding the $7.16 projected by analysts, citing outperformance in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, the company continued to project a cautious outlook for the rest of the year, noting that concerns over rising cost trends and macro headwinds remain. For the quarter, CVS recorded $100.4B in revenue with ~6% YoY growth as its Health Care Benefits segment added $36.0B to the topline with ~3% YoY growth thanks mainly to its Government business. The segment also recorded $3.0B in adjusted operating income, indicating ~53% YoY growth as its medical benefit ratio dropped to 84.6% from 87.3% in the prior year period amid headwinds from its Government business. However, its medical membership fell roughly 600K to 26M at the end of the quarter due to the company’s decision to exit the individual exchange business in 2026. Meanwhile, CVS’ Health Services segment, which operates its pharmacy benefit manager Caremark, added $48.2B to the topline with ~11% YoY growth, while revenue from its Pharmacy & Consumer Wellness segment held steady at $32.0B. As for earnings, the company’s adjusted EPS reached $2.57, beating the consensus by $0.36 with ~14% YoY growth, mainly due to higher adjusted operating income in the Health Care Benefits segment. More on CVS CVS Health: A Diversified Income Play With Improving MA Rate Visibility For 2027 CVS Health's Discounted Buying Opportunity Is Here - Robust Fundamentals And Secure Dividends CVS Health Corporation (CVS) Presents at Leerink Global Healthcare Conference 2026 Transcript CVS Non-GAA...
Welcome to Tech In Depth, our daily newsletter about the business of tech from Bloomberg’s journalists around the world. Today, Takashi Mochizuki and Alice French look at the contrast between Nintendo’s business success and faltering share price. Tech Across the Globe Blackstone, KKR prepare for AI: The investment firms are in talks with Alphabet to give companies they own access to Google’s AI to...
Welcome to Tech In Depth, our daily newsletter about the business of tech from Bloomberg’s journalists around the world. Today, Takashi Mochizuki and Alice French look at the contrast between Nintendo’s business success and faltering share price. Tech Across the Globe Blackstone, KKR prepare for AI: The investment firms are in talks with Alphabet to give companies they own access to Google’s AI tools. Read what spurred the discussions . Trillion-dollar club: Samsung became the second Asian company in history, after TSMC, to surpass $1 trillion in market value after another day of furious buying of memory chip stocks. It’s now worth roughly as much as Walmart . Apple’s AI equanimity: The iPhone maker will let users choose from a range of AI models to power features on its devices. This is how it fits with the company’s strategy . Revalued Enter, an AI legal startup based in São Paulo , tripled its valuation to $1.2 billion in a funding round that raised $100 million. The fundraising was led by Peter Thiel’s Founders Fund. Enter’s customers in Brazil include Airbnb and Latam Airlines. Danger abounds Since the launch of its Switch 2 in June, Nintendo has been on a hot streak of successful game releases, punctuated with popular theme park attractions and another winning cinema release last month. It should be riding high, yet its Tokyo-traded shares are on their worst run in a decade. The contradiction, and the debate in investor circles, centers on the price of the Switch 2 console itself. Many now believe that Nintendo simply must raise prices when it reports earnings this Friday, to guard against escalating costs and appease an anxious investor community. Others worry about the impact on demand, though that may be short-lived, unlike the share price pressure. Nintendo’s stock has retreated for five straight months, marking the longest sustained decline since 2016. Its path decoupled from the Nikkei 225 benchmark in September — when signs of the memory chip supply cru...